Peter McSweeney is an Oncology physician affiliated with Mesoblast. OpenAlex indexes 238 publications with 24,381 citations (h-index 61); ClinicalTrials.gov lists 4 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1721 E 19th Ave Ste 300
Denver, CO 802181258
Telephone
720-754-4800Registry record last updated 22 Jun 2016.
Clinical trials
- SCOT Scleroderma Treatment Alternative Registry (STAR Registry)
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation
Sponsor: Colorado Blood Cancer Institute
- Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor
Sponsor: Colorado Blood Cancer Institute
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
10 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20253 payments
- Mesoblast, Inc.Program year20251 payment
- ABBVIE INC.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
New England Journal of Medicine
2021 - Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma
British Journal of Haematology
2021 - KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
New England Journal of Medicine
2020
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”